medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2006, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2006; 51 (3)

Oral dexmedetomidine as preanesthetic medication in pediatric patients. Dose comparison and clinical side effects

Álvarez MI, Gallardo AL, Martínez LE, Alonso MA, Gutiérrez GA, Mendoza RR, Arturo GAP

Language: Spanish
References: 24
Page: 113-119
PDF size: 102.81 Kb.


ABSTRACT

Dexmedetomidine, is an α2-adrenoreceptor agonist drug, it has been used as a sedative, analgesic, anxiolytic and as anesthetic coadjuvant. The purpose of this study is to evaluate its efficacy when administered orally as hypnotic and anxiolytic used in different doses as preanesthetic medication and its adverse effects in pediatric patients. In a randomized, double-blind study oral dexmedetomidine was administered. Thirty unmedicated children (ASA PS I or II, ages 1-10 yr) were randomly assigned to one of three groups receiving dexmedetomidine 2, 3 or 4 µg.kg-1 respectively 30 minutes before the separation from parents. Heart rate, arterial oxygen saturation, sedation and anxiolysis scores were recorded before premedication, every five minutes for 30 min and then during induction of anaesthesia, every 5 min in transanesthesic period, every 15 min in recovery room and every 30 min until discharged from hospital. We found that heart rate, reduced 30 minutes after the administration of dexmedetomidine in the 3 groups, arterial oxygen saturation was unchanged during the study. Time to achieve an Observer’s Assessment of Alertness/Sedation score (OAA/S) of 18 was not different between groups. Mean times to discharge from hospital were significantly higher in group III. This study shows the administration of dexmedetomidine orally as a preanesthetic drug in pediatric patients, without hemodynamic or ventilatory adverse effects, offering a small and insipid volume.


REFERENCES

  1. Spear R, Yaster M, Berkowitz I, Maxwell L, Bender K, Naclerio R, Manolio T, Nichols D: Preinduction of anesthesia in children with rectally administered midazolam. Anesthesiology 1990; 74: 670-674.

  2. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonist: their pharmacology and therapeutic role. Anaesthesia 1999; 54: 146-165.

  3. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000; 93: 1345-1350.

  4. MacMillian LB, Hein L, Smith MS, Piascik, Limbird LE. Central hypotensive effects of the alpha 2a-adrenergic receptor subtype. Science 1996; 273: 801-803.

  5. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000; 35: 609–613.

  6. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M: Adrenergic a2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 1998; 18: 3035–3042.

  7. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs 2000; 59: 263–268.

  8. Gertler R, Brown C, Michell D, Silvius E. Dexmedetomidine: A novel sedative-analgesic agent. BUMC proceedings 2001; 14: 13-21.

  9. Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54: 1136-1142.

  10. Ben-Abraham R, Ogorek D, Weinbroum AA. Dexmedetomidine: A promising agent for anesthesia and perioperative care. Isr Med Assoc J 2000; 2: 793-796.

  11. Tobias JD, Berkensbosch JW. Initial experience with dexmedetomidine in pediatric-aged patients. Paediatr Anaesth 2002; 12: 171-175.

  12. Koroglu A, Demirbilek H, Teksan O. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: Preliminary results. Br J Anaesth 2005; 94: 821-824.

  13. Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol 2003; 15: 263-266.

  14. Tobias JD, Berkensbosch JW. Additional experience with dexmedetomidine in pediatric patients. South Med J 2003; 96: 871-875.

  15. Berkenbosch JW, Zub D, Tobias JD. Preliminary experience with oral dexmedetomidine in children: 61. Pediatr Crit Care Med 2005; 6: 117.

  16. Anttila M, Penttilä J, Helminen A. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 2003; 56: 691-693.

  17. Chernick DA, Ghouri D, Laine H. Validity and reliability of the observer´s assessment of alertness/sedation scale: Study with intravenous midazolam. J Clin Psychopharmacol 1990; 10: 244-251.

  18. Brennan LJ. Modern day-case anaesthesia for children. Br J Anaesth 1999; 83: 91-103.

  19. Ebert TJ, Hall JE, Barney JA. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93: 382-394.

  20. Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. Pediatr Crit Care Med 2003; 4: 203-205.

  21. Peden CJ, Cloote AH, Stratford N. The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia 2001; 56: 408-413.

  22. Malviya S, Voepel LT, Eldevik OP. Sedation and general anaesthesia in children undergoing MRI and CT: adverse events and outcomes. Br J Anaesth 2000; 84: 743-748.

  23. Hall JE, Uhrich TD, Barney JA. Sedative, amnestic and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000; 90: 699-705.

  24. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000; 4: 302-308.




2020     |     www.medigraphic.com